ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

Abstract Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas J. Herzog, Thomas C. Krivak, Stephen Bush, John P. Diaz, Scott Lentz, Navya Nair, Nadim Bou Zgheib, Camille Gunderson-Jackson, Abhijit Barve, Krista L. Denning, Seth T. Lirette, Candace M. Howard, Jagan Valluri, Pier Paolo Claudio
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-00874-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items